Literature DB >> 21029028

New delivery strategies for the old pentavalent antimonial drugs.

Frédéric Frézard1, Cynthia Demicheli.   

Abstract

IMPORTANCE OF THE FIELD: Pentavalent antimonials are the first-line drugs for treatment of the major tropical disease leishmaniasis. However, their use is limited by the need for daily parenteral administration, their severe side effects and treatment failures. As leishmaniasis belongs to the group of neglected diseases, the improvement of old drugs through new delivery approaches has more support than the development of new chemical entities. AREAS COVERED IN THIS REVIEW: The review covers, from 1977 to the present, the progress achieved towards pharmaceutically acceptable liposome-based formulations of antimonials, identification of specific ligands for improved targeting of infected macrophages and new approaches for oral and topical delivery of antimonial drugs. WHAT THE READER WILL GAIN: Insights into the most promising delivery strategies to improve antimonial therapy and the chemical basis and future directions for achieving innovative orally and topically effective formulations. TAKE HOME MESSAGE: The development of drug delivery strategies for the old pentavalent antimonials is a still growing and promising field, with expected innovations in the near future from improved knowledge of antimony chemistry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029028     DOI: 10.1517/17425247.2010.529897

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  21 in total

1.  A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Daysiane de Oliveira; Bethina T Steiner; Vívian T Martins; Luísa Perin; Amanda S Machado; Thaís T O Santos; Grasiele S V Tavares; João A Oliveira-da-Silva; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Antônio L Teixeira; Maria V Humbert; Eduardo A F Coelho; Myron Christodoulides
Journal:  NPJ Vaccines       Date:  2020-08-13       Impact factor: 7.344

2.  Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.

Authors:  Levi Eduardo Soares Reis; Rory Cristiane Fortes de Brito; Jamille Mirelle de Oliveira Cardoso; Fernando Augusto Siqueira Mathias; Rodrigo Dian Oliveira Aguiar Soares; Claudia Martins Carneiro; Paula Melo de Abreu Vieira; Guilherme Santos Ramos; Frédéric Jean Georges Frézard; Bruno Mendes Roatt; Alexandre Barbosa Reis
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite.

Authors:  Marcela Luísa Gomes; Gilson DeFreitas-Silva; Priscila Gomes dos Reis; Maria Norma Melo; Frédéric Frézard; Cynthia Demicheli; Ynara Marina Idemori
Journal:  J Biol Inorg Chem       Date:  2015-05-01       Impact factor: 3.358

4.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

5.  Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis.

Authors:  Flaviana R Fernandes; Weverson A Ferreira; Mariana A Campos; Guilherme S Ramos; Kelly C Kato; Gregório G Almeida; José D Corrêa; Maria N Melo; Cynthia Demicheli; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

6.  Knockdown of Host Antioxidant Defense Genes Enhances the Effect of Glucantime on Intracellular Leishmania braziliensis in Human Macrophages.

Authors:  Jair Téllez; Ibeth Romero; Maurilio José Soares; Mario Steindel; Alvaro José Romanha
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.

Authors:  Sydnei M da Silva; Izabela F G Amorim; Raul R Ribeiro; Erly G Azevedo; Cynthia Demicheli; Maria N Melo; Wagner L Tafuri; Nelder F Gontijo; Marilene S M Michalick; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2012-03-12       Impact factor: 5.191

8.  Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.

Authors:  Cristiano C P Dos Santos; Guilherme S Ramos; Renata C De Paula; Karen F Faria; Paulo O L Moreira; Ramon A Pereira; Maria N Melo; Wagner L Tafuri; Cynthia Demicheli; Raul R Ribeiro; Erly G Azevedo; Rubens Do Monte-Neto; Sydnei M Da Silva; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

9.  Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.

Authors:  Flávia M Ferreira; Renata A O Castro; Mauricio A Batista; Fernanda M O Rossi; Denise Silveira-Lemos; Frédéric Frézard; Sandra A L Moura; Simone A Rezende
Journal:  Parasitol Res       Date:  2013-11-30       Impact factor: 2.289

10.  In vitro and in vivo evaluation of SU-8 biocompatibility.

Authors:  Krishnamurthy V Nemani; Karen L Moodie; Jeoffry B Brennick; Alison Su; Barjor Gimi
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2013-07-12       Impact factor: 7.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.